Text Size

Cocaine Abuse and Attention Deficit Disorder - 3

This study has been completed.
Sponsor:
Collaborator:
New York State Psychiatric Institute
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000268
First received: September 20, 1999
Last updated: November 3, 2005
Last verified: May 1995
History of Changes
  Purpose

The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder


Condition Intervention
Cocaine-Related Disorders
 Drug: Bupropion

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Cocaine Abuse and Attention Deficit Disorder

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Craving
  • Drug use
  • ADHD symptoms
  • Improvement in functioning
  • Tolerability

Estimated Enrollment: 32
Study Start Date: May 1995
Estimated Study Completion Date: November 1998
Detailed Description:

To evaluate the safety and efficacy of methylphenidate and bupropion in treating individuals with adult Attention Deficit Disorder.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

current adult ADHD current cocaine dependence

Exclusion Criteria:

no current major depression

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000268

Locations
United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York State Psychiatric Institute
Investigators
Principal Investigator: Herbert Kleber, M.D. New York State Psychiatric Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000268     History of Changes
Other Study ID Numbers: NIDA-09236-3, P50-09236-3
Study First Received: September 20, 1999
Last Updated: November 3, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Attention Deficit Disorder with Hyperactivity
Substance-Related Disorders
Mental Disorders
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Bupropion
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
 Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 18, 2013